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1. Introduction 
Echinococcosis is a parasitic zoonosis caused by adult or larval stages of cestodes belonging 
to the genus Echinococcus (family Taeniidae). There are two major species of echinococcosis 
which are Echinococcus granulosus and Echinococcus multilocularis, which cause cystic 
echinococcosis (CE) and alveolar echinococcosis (AE), respectively. In endemic areas, the 
diseases are important for both medical and social aspects. CE and AE are both serious 
diseases, the latter especially so, with a high fatality rate and poor prognosis if careful 
clinical management is not carried out (Zhang&McManus,2006). 
The annual incidence of CE ranges from <1 to 200 per 100,000 inhabitants, whereas the 
annual incidence of AE ranges from 0.03 to 1.2 per 100,000. It may be significantly higher in 
certain endemic areas. The global human burden of CE averages 285,000 diasability-
adjusted life years (DALYs) and causes an annual economic loss of US $194,000,000. The 
mortality is also high, especially in untreated cases. The mortality, which is higher in AE 
than CE, reaches about %90 in untreated or inadequatelly treated cases of AE (Brunetti, 
2010). 
In this chapter, we evaluated this complex parazitic disease, which is a challange for the 
physicians in both diagnostic and theraupetic aspects. We also mentioned about the social 
and economic burden of the disease and investigated the control and preventive 
measures. 
2. Epidemiology 
2.1 Epidemiology of E. granulosis 
CE has a serious impact on human health and livestock production in endemic areas such as 
in South and Central America, the Middle East, some sub-Saharan African countries, China, 
and the former Soviet Union. The overall prevelance of echinococcal infection is not clear 
because of the lack of systemic population surveys.  
In some European countries or regions, the annual incidences of hospital cases of human CE 
vary between 1 and 8 per 100,000 population. High incidence rates or prevelances have also 
been recorded from countries in northern and eastern Africa (prevalences of 3%) and South 
America (for example; an annual incidence of 9.2 per 100,000 population in Uruguay in 
1995).(Eckert&Deplazes,2004) 
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Epidemiological studies in endemic villages of Peru have shown human infection 
prevalences ranging from 5.5% to 9.1%, with the prevalence of CE in sheep and cattle as 
high as 77% and 68%, respectively(Moro et al. 2011). 
A recent surveyin Spain showed human CE annual incidence rates in the range of 1.1 to 3.4 
cases per 105 person-years, in combination with ovine or bovine CE prevalence proportions 
of up to 23%.( Benner et al.2010) 
In Chına where CE is highly endemic, farmers (76%) were the main group of echinococcosis 
patients, followed by students (12.4%), workers including those self employed (5.2%), cadres 
(4.8%) and others (2%). Females outnumbered male patients with a ratio of 1.38. For 2000, 
the population ratio showed a significantly higher morbidity in females for echinococcosis 
(Yang et al,2010). 
Cystic echinococcosis(CE)  is an endemic zoonosis in Iran particularly in rural regions. 
Harandi et al prepared a study  to determine the prevalence of CE among rural communities 
in Kerman using ultrasonography (US) and serology in southeastern Iran. Two hydatid 
cases (0.2%) were detected by ultrasound. Serological results showed 7.3% seropositivity, 
and females (8.3%) were significantly more positive than males (2.1%). There were 
significant difference between CE seropositivity and sex, age and occupation. Dog 
ownership does not appear to be a significant risk factor for CE in the region. The serological 
study showed that many people, especially women, had been exposed to Echinococcus eggs 
and had seroconverted but were not infected (Harandi et al, 2011). 
Greece is another cauntry where national surveillance programmes are running for Cystic 
echinococcosis. The prevelance of human hydatidosis, declined from an annual incidence of 
14.8 per 100,000 inhabitants during 1967-1971 to 0.3 in 2008.  Late surveys revealed that in 
Greece the prevalence of echinococcosis was 23-39.2% for sheep, 7.6-14.7% for goats, 0% in 
cattle and 0.6% in pigs (Sotirakis&Chaligiannis,2010). 
The prevelance of CE in sheep reported to European Food Safety Authority (EFSA) in 2008 
is  4.3% in Bulgaria, 11.3% in Italy , 6.7% in Poland  and 5% in Romania. High levels of sheep 
CE were also reported in Portugal and Greece in 2007 (9.4% and 3.9%, respectively) 
(http://www.efsa.europa.eu/en/scdocs/scdoc/1496.htm) 
Mastin et al. evaluated the prevalence of canine echinococcosis by using coproantigen in 
mid/south Wales. The coproantigen prevalence identified in dogs was 10.6% , with 20.6%  
of farms  containing at least one coproantigen-positive dog (Mastin et al, 2011).  
2.2 Epidemiology of E. multilocularis 
Although generally rare, AE deserves public health attention due to the high fatality rate of 
untreated patients and the high costs of treatment. Echinococcus multilocularis occurs 
across the Northern Hemisphere, in parts of central Europe, Russia, western China, areas of 
North America, and Northern Africa. In Europe, the endemic area of Echinococcus 
multilocularis covers parts of the western continent (France, Benelux States) and all 
countries of central Europe, including the Baltic States. Furthermore, foci exist in Denmark 
and on the Norwegian Svalbard Island In Eastern Europe, Russia belongs to the endemic 
area, and the parasite has also been found in Byelorussia, Ukraine, Moldavia, and 
Armenia(Jenkins et al,2005). 
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Ultrasonographic and immunodiagnostic surveys (1991 to 1997) have revealed a very high 
prevalence within a focus in China, where 135 (4%) of 3,331 people examined had 
documented AE (Craig et al,2000). A recent study from Western China including the Tibetan 
Plateau reported total prevalence rate of 8.1% (3.9% for alveolar echinococcosis and 4.2% for 
cystic echinococcosis) which is the highest level for echinococcosis ever reported in the 
world (Li et al,2010).  
3. Pathogenesis 
3.1 Pathogenesis of E. granulosus 
The hydatid cyst has three layers:  
1. The outer pericyst is a dense and fibrous zone and composed of modified host cells. It is 
the protective layer.  
2. The middle is the laminated membrane. It is acellular and allows the passage of 
nutrients. 
3. The inner layer is the germinative layer which gives rise to the hydatid fluid and small 
secondary cysts (brood capsules) which bud internally from this layer. Fragmentation 
of the germinative layer and brood capsules gives rise to daughter cysts. These may 
develop within the original cyst or separately. 
The middle laminated membrane and the germinal layer form the true wall of the cyst, 
usually referred to as the endocyst, although the acellular laminated membrane is 
occasionally referred to as the ectocyst (Pedrosa et al,2000).  Daughter vesicles (brood 
capsules) are small spheres that contain the protoscolices and are formed from rests of the 
germinal layer. 10-12 months after infection, protoscolices are produced in broad capsules. 
Cysts containing protoscolices are fertile and can produce daughter cysts, whereas cysts 
without protoscolices are sterile. Before becoming daughter cysts, these daughter vesicles 
are attached by a pedicle to the germinal layer of the mother cyst. At gross examination, the 
vesicles resemble a bunch of grapes. Daughter cysts may grow through the wall of the 
mother cyst, particularly in bone disease (Pedrosa et al,2000) 
The pattern of E. granulosus infection varies in different geographic regions and among 
different populations. Among patients in Turkana, Kenya, for example, many cysts are 
large, unilocular and fertile. In contrast, cysts among individual in the northern hemisphere 
tend to be calcified, small, and infertile. The time between infection and diagnosis, 
intraspecies variation of the parasite and host differences (immunologic, genetic and/or 
nutritional) can influence these variations (Eckert&Deplazes,2004). 
3.2 Pathogenesis of E. multilocularis  
E. multilocularis can cause severe infection in humans. The metacestode tissue invades and 
destroys tissue, extends beyond organ borders into adjacent structures, and can metastasize 
to distant sites. In macroscopic sections of the human liver, the metacestodes of E. 
multilocularis exhibit an alveolar spongy structure composed of numerous irregular vesicles 
with diameters between less than 1 and 20 mm. There is no sharp demarcation from 
surrounding organ tissue. The vesicles are embedded in a very dense and hard fibrous 
stroma so, fibrosis and in some cases central necrosis are hallmarks of alveolar 
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echinococcosis. The lack of limiting membrane allows exogenous budding, proliferation and 
infiltration into adjacent tissues, resulting in necrosis of surrounding host tissue. 
(Ammann& Eckert,1996; Kern 2010). 
In the human host, there may be adjacent organ metastases (gall bladder, pancreas, 
diaphragm,etc.)  or spread to distant localizations (lungs, bones, muscles, skin, brain, spine, 
etc.) by haematogenous or lymphatic route. The morphological structure of the E. 
multilocularis metacestode in other organs is essentially similar to that in the liver. 
Microscopically, the cysts are composed of a thin laminated layer with minimal or no 
germinative layer.  Brood capsules and protoscolices form in less than 10 percent of these 
cysts. The metacestode of E. multilocularis proliferate either by exogeneous budding and 
separation of smaller daughter vesicles from larger old ones, or by endogenous formation of 
small daughter vesicles originating from the germinal layer of older large vesicles (Hemphil 
et al 2010). Metacestodes can die spontaneously, followed by degeneration (Rausch et al, 
1987). 
4. Genetic variation and immunity 
E granulosus shows genetic variations which are important for the formation of different 
strains. There are 10 distinct genetic types of E Granulosis ( genotypes G1-10 ) with different 
biological properties important for life cycle patterns, host specificity, development rate, 
antigenicity, transmission dynamics, sensitivity to chemotherapeutic agents and pathology 
with important implications for the design and development of vaccines, diagnostic 
reagents and drugs (Zhang&McManus,2006).On the other hand, E multilocularis lacks this 
property and exhibit limited genetic variation. 
Echinococcosis is mostly asymptomatic for a long period after infection but hosts’ immune 
responce is continuous. 
4.1 Immune responce against Cystic Echinococcosis (CE) 
The immune responce against early E. granulosus infection begins after the oncosphere 
locates a target organ and forms hydatid cyst that causes infiltration of macrophages and 
eosinophil cells, and low-level polarized Th1 responses (Zhang&McManus,2006). This 
generally does not result in a severe inflammatory response and aged cysts tend to become 
surrounded by a fibrous layer that separates the laminated layer from host tissue. Antibody 
responses are also weak and are, normally, undetectable in the early two to three weeks 
following infection ( Zhang et al, 2003). 
As the parasite grows, it produces significant quantities of antigens that modulate the 
immune responses which include polarized Th2 responses, balanced with Th1 responses. 
Elevation of IL-4, IL-5, IL-6 and IL-10 also has been recorded in most hydatid patients where 
cytokine levels have been measured. In addition, IgG, especially IgG1 and IgG4, IgE and 
IgM are elevated as the cyst grows and becomes established. When a cyst dies naturally, is 
killed by chemotherapy treatment or is removed by surgery, Th2 responses drop rapidly, 
and Th1 responses become dominant. This can be interpreted as Th1 lymphocytes 
contribute significantly to the inactive stage of hydatid disease, with Th2 lymphocytes being 
more important in the active and transitional stages.  IgG levels can be maintained in 
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humans for several years after the cyst has been removed. In case of relaps, the Th2 
responses regenerate very quickly. (Zhang&McManus,2006). These patients have high levels 
of IgE and IgG4, increased levels of IL-5, IL4, and IL-10, and low levels of IFN-γ compared 
to patients with a primary infection (Rigano et al,1995a; Rigano et al,1996). Patients with a 
primary infection have higher levels of IL-2, IFN-γ, and IL-5. The high level of IL-5 is in 
agreement with the high levels of IgG4 and IgE observed (Rigano et al,1996). There is a 
significant correlation between IgE and IgG4 production in sera from patients with hydatid 
disease and a trend toward increased IL-4 and IL-10 levels in patients who are high 
producers of IgE and IgG4 ( Rigano,1995b;  Zang et al, 2003) Serum IL-4 may be a useful 
marker for the follow up of patients with CE (Rigano et al, 1999). 
Eosinophilis and  high levels of IgE are the common consequences of infection by helminths 
(Bell,1996; Capron,1992). They may be important as a defense against the tissue stages of 
parasites that are too large to be phagocytosed (Haynes,1990). IgE-dependent mast cell 
reaction can be involved both in localization of eosinophils near the parasite and enhancing 
their antiparasitic functions (Bell,1996). Eosinophils are less phagocytic than neutrophils, 
but, like neutrophils, they can kill larval stages of parasites such as Echinococcus.  Their 
activities are also enhanced by cytokines (Rainbird et al,1998; Meeusen&Balic, 2000). 
4.2 Immune responce against Alveolar Echinococcosis (AE) 
Human AE is a chronic and often fatal disease which is characterized by slowly developing 
cysts, mainly in the liver. It destroys the liver parenchyma, bile ducts and blood vessels 
forming necrotic cavities, causes biliary obstruction and portal hypertension. Like CE 
infection, Th1 responses predominate in the early stages of AE infection, with the immune 
response switching to a Th2 polarized profile in later progression (Zhang &McManus ,2006; 
Wei et al, 2004).  Pathological examination of AE infection shows  large granulomatous 
infiltrate surrounding the parasitic lesions (Vuitton et al., 1989; Ricard-Blum et al., 1996; 
Grenard et al., 2001).The cells involved in the formation of the periparasitic granuloma are 
mainly macrophages, myofibroblasts and T lymphocytes. In patients with abortive or dead 
lesions, a large number of CD4 T lymphocytes are present, whereas patients with active 
metacestodes display a significant increase in activation of predominantly CD8 T cells 
(Manfras et al., 2002), indicating that CD4 T cells play a role in the killing mechanism. In the 
absence of T cells, the cellular immune response to infection decreases that will disturb the 
hepatic granuloma formation. Today it is known that CD4 T cells play in limiting E. 
multilocularis proliferation, while CD8 T and B cells appeared to play a minor role in the 
control of parasite growth. (Dai et al 2004) 
Significantly higher levels of IL-10  and IL-5 have been found in AE patients than in controls 
(Wellinghausen et al,1999; Sturn et al,1995; Riley et al,1985) . In contrast, IL-4 was 
measurable in only a minority of patients and controls. IL-12 levels were comparable 
between AE patients and controls and showed a similar distribution pattern to IL-10 with 
regard to disease progression (Zang et al,2003) AE patients experiencing a relapse of the 
disease have a tendency to increased production of IL-5 but lower IFN-γ_ production 
accompanied by significantly higher levels of IgE and IgG4 compared to patients with a 
primary infection (Godot et al,1997). 
One of the most important issue about E. multilocularis is the interplay between the 
immunity of the host and the parasite. The disease spectrum is clearly dependent on the 
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genetic background of the host as well as on acquired disturbances of Th1-related immunity. 
The laminated layer of the metacestode, and especially its carbohydrate components, plays a 
major role in tolerance induction. Th2-type and anti-inflammatory cytokines, IL-10 and 
TGF-beta, as well as nitric oxide, are involved in the maintenance of tolerance and partial 
inhibition of cytotoxic mechanisms. The production of nitric oxide by intraperitoneal 
macrophages of mice during secondary infection with Echinococcus multilocularis mediates 
immunosuppression at early and late stages of infection. Results of these studies in the 
experimental mouse model and in patients suggest that immune modulation with cytokines, 
such as interferon-alpha, or with specific antigens could be used in the future to treat 
patients with alveolar echinococcosis and/or to prevent this very severe parasitic disease 
(Dai et al,2003; Vuitton&Gottstein,2010) 
5. Life cycle and transmission 
The life cycle of Echinococcus includes a definitive host (usually dogs or related species) and 
an intermediate host (herbivores such as sheep, horses, cattle, pigs, goats and camels,etc ). 
Humans are incidental hosts; they do not play a role in the transmission cycle. E. granulosus 
adult tapeworms are usually found in dogs or other canids. E. multilocularis adult 
tapeworms are usually found in foxes, other canids, or occasionally cats. 
The tapeworm of E. granulosus in definitive host is composed of at least three proglottid 
segments which have both male and female sexual organs, which are about 2-7 mm long. 
They can produce thousands of parasite eggs 30 to 40 µm in size containing embryos 
(oncospheres).  Gravid proglottids or released eggs are shed in the faeces and, following 
their ingestion by a human or ungulate host, an oncosphere larva is released that penetrates 
the intestinal epithelium into the lamina propria. This is then transported passively through 
blood or lymph to the target organs where it develops into a hydatid cyst.  About 5 days 
after ingestion of eggs of E. granulosus, the metacestode forms. It is a small vesicle which is 
about 60 to70 mm in diameter consisting of an internal cellular layer (germinal layer) and an 
outer acellular, laminated layer. Endocyst gradually expands and induces a granulomatous 
host reaction, followed by a fibrous tissue reaction and the formation of a connective tissue 
layer (pericyst). E. granulosus cysts in the human body is highly variable in size and usually 
ranges between 1 and 15 cm but much larger cysts (20 cm in diameter) may also ocur 
(Ammann&Eckert,1996; Eckert&Plazes ,2004). 
E. multilocularis worms are up to 4 mm long with two to six proglottic segments. The 
metacestode stage of E. multilocularis is a tumor-like multivesicular, infiltrating structure 
consisting of numerous small vesicles embedded in stroma of connective tissue; the larval 
mass usually contains a semisolid matrix rather than fluid (Eckert & Plazes, 2004). This 
exogenous tumour-like proliferation, which leads to infiltration of the affected organs and, 
in progressive cases, to severe disease and even death. The single vesicle has a wall structure 
similar to that of the metacestode of E. granulosus (germinal and laminated layer). 
E. granulosus eggs can survive under humid conditions for several weeks or months in areas 
of warm and cold climates,but they are sensitive to desiccation (Eckert et al,2001). Eggs of E. 
multilocularis remain infective for approximately 1 year in a suitable, moist environment at  
lower temperatures, but they are sensitive to desiccation and high temperatures (Veit et 
al,1995). These eggs can survive at(-) 50°C for 24 h but are killed at (-) 
70°C within 96 h and at (-)80 to (-)83°C within 48 h. Deep-freezing at (-)70°C for at least 4 
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days or at (-)80°C for at least 2 days is recommended for inactivating E. multilocularis eggs in 
carcasses or intestines of final hosts or in fecal material before examination in the laboratory.  
Humans acquire primary CE by oral uptake of E. granulosus eggs excreted by infected 
carnivores. The infection may be acquired by handling infected definitive hosts, egg-
containing feces, or egg-contaminated plants or soil followed by direct hand-to-mouth 
transfer . Transmission frequently occurs in settings where dogs eat the viscera of 
slaughtered animals. The dogs then excrete infectious eggs in their feces, which are passed 
on to other animals or humans via fecal-oral transmission. This may occur via 
environmental contamination of water and cultivated vegetables, or contact between 
infected domestic dogs and humans (often in children). It has been shown that Echinococcus 
eggs adhere to the coat of dogs, particularly to the hairs around the anus and on the thighs, 
muzzles, and paws. It is generally assumed that humans can become exposed to the eggs of 
E. multilocularis by handling infected definitive hosts or by ingesting food or water 
contaminated with eggs. Direct transmission of echinococcosis from human to human does 
not occur since two mammalian species are required for completion of the life cycle. 
Prenatal transfer of E. granulosus does not play a role (Conn,1994; Eckert et al, 2001). 
The identification of risk factors of transmission is also an important issue. In a case-control 
study in Argentina, spending the first years of life surrounded by a large number of dogs 
was found to be an important risk factor (Larrieu et al,2002). In Tibetan aeras of China 
(Sichuan), increased risks for CE were associated with nomadic life, age, playing with dogs, 
not protecting food from flies, and raising yaks or sheep (Wang et al,2001). In another study, 
risk factors for human cystic echinococcosis were found to be pastoral occupation,  history 
of dog ownership, poor education, age, sex, and drinking water source (McManus,2003). 
Domestic dogs and cats can also be infected with E. multilocularis. In a previous study in 
France, 5.6% of 36 dogs were identified as carriers of E. multilocularis, and in a further five 
studies in Germany and France, 0.5 to 3.7% of cats (58 of 498) were identified (by necropsy) 
as carriers (Eckert et al,2000). In an area of endemic infection in eastern Switzerland with an 
average prevalence of E. multilocularis in foxes of approximately 33%, only 0.30% of 660 dogs 
and 0.38% of 265 cats from “normal” populations were parasite carriers (Deplazes,1999). 
Dogs are highly susceptible to E. multilocularis, but cats appear to have a lower and a more 
variable degree of susceptibility, as observed both in several older and in more recent 
experimental studies (Jenkins&roming,2000). However, naturally infected cats can harbor 
small numbers of E. multilocularis worms containing fully developed eggs and are therefore 
potential sources of infection. 
6. Clinical aspects of Echinococcus disease 
6.1 Clinics in Echinococcus granulosus  
CE can be seen in all age groups. In endemic areas, most hospital cases are recorded in the 
age groups between 21 and 40 years. Many infections are acquired in childhood but do not 
cause clinical manifestations until adulthood. The initial phase of primary infection is 
always asymptomatic. Latent periods may be very long such as 50 years. An analysis of 
8,596 individuals in areas of endemic infection in Uruguay has revealed a significant age 
dependent increase of hepatic cysts detectable by ultrasonography from 0.33% in the age 
group from 0 to 9 years to 3.80% in the age group from 70 to 79 years. Similar observations 
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were made in other areas of endemic infection. Morbidity is higher in younger individuals 
aged between 6 and 20 years (Eckert&Deplazes,2003) 
The cysts of E granulosis may grow at a rate of 1-5 cm yearly or may persist without 
changes for years (Brunetti et al,2010). Hydatid cysts can be found in any part of the body, 
but liver is the most affected organ (Figure 1). Lung, brain, muscle, kidney, bone, heart and 
pancreas can be involved also. Up to 80% of patients infected with E granulosus have single 
organ involvement and a solitary cyst located in the liver (Yang et al,2006;) or lung 
(Brunetti&Junghanss,2009). The clinical presentation of E. granulosus infection depends 
upon the site of the cysts and their size. Small and/or calcified cysts may remain 
asymptomatic indefinitely. In larger cysts, there may be symptoms due to compression or 
rupture into neighbouring structures. (Brunetti et al,2010). 
 
Fig. 1. CT examination shows two hypodense cystic liver lesions. Well defined fluid 
collections, consistent with cyst hydatid. 
6.1.1 Liver involvement  
E. granulosus infection of the liver frequently produces no symptoms. The right lobe is 
affected in 60 to 85 percent of cases. Significant symptoms are unusual before the cyst has 
reached at least 10 cm in diameter. The rate of growth of cysts is variable depending on the 
strain differences and the organ involved. Typical measurements state that the average cyst 
growth is 1 cm to 1.5 cm/year. Moreover, small, well-encapsulated, or calcified cysts 
typically do not elicit major pathology. Hydatid hepatic cyst symptoms include pain in the 
upper abdominal region, hepatomegaly, cholestasis, biliary cirrhosis, portal hypertension, 
and ascites. Serious complications include cyst rupture either into the peritoneal cavity 
resulting in anaphylaxis or secondary cystic Echinococcosis, cyst rupture into the biliary tree 
resulting in cholangitis and cholestasis. Secondary bacterial infection of the cysts can result 
in liver abscesses.(Scherer et al,2009) 
In a study of Avgerinos et al. where they shared their 20 year experience with liver 
hydatidosis, the presenting symptoms or findings leading to the diagnosis of liver 
echinococcosis were jaundice (six cases, 17%), abdominal pain (five cases, 14%), 
gastrointestinal discomfort of the upper abdomen (e.g. nausea, vomiting, distention, anorexia) 
(two cases, 6%), acute pancreatitis (one case, 3%) and portal hypertension (one case, 3%). The 
rest of the cases were diagnosed incidentally (20 cases, 57%). (Avgerinos et al,2006) 
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6.1.2 Lung involvement  
The ratio of lung:liver involvement is higher in children than in adults. Most pulmonary 
cases are discovered incidentally on routine radiograph evaluation; also most infected 
individuals remain asymptomatic until the cyst enlarges sufficiently to cause 
symptoms(Santivanez &Garcia,2010). Approximately 60 percent of pulmonary hydatid 
disease affects the right lung and 50 to 60 percent involve the lower lobes. Multiple cysts are 
common. Approximately 20 percent of patients with lung cysts also have liver cysts. 
Symptoms are usually caused by mass effect from the cyst. Complications such as cyst 
rupture and aggregated infection change the clinical presentation, producing cough, chest 
pain, hemoptysis, or vomiting. If cysts rupture into the pleural space, a pleural effusion or 
empyema may develop. Diagnosis is obtained by chest radiographs or computed 
tomography, and supported by serology. (Baden&Elliot,2003; Santivanez &Garcia,2010) 
6.1.3 Other organs 
Involvement of heart, central nervous system, kidneys, bone and eye have been reported in 
the literature. Echinococcal infections of these organs are rare but can lead to significant 
morbidity and mortality.Cardiac involvement is a rare, but potentially a very serious 
complication of the hydatid disease. The diagnosis of cardiac cyst hydatid may be difficult 
due to the nonspecific symptoms and varying clinical presentations. The most common 
localizations within the heart are left ventricle, interventricular septum, right ventricle, 
pericardium and right or left atrium. Infection of the heart can result in mechanical rupture 
with widespread dissemination or pericardial tamponade (Demircan et al,2010) 
Cerebral hydatid cysts are usually supratentorial, whereas infratentorial lesions are quite 
rare. Clinically the disease presents as intracranial space occupying lesion and is more 
common in children. It can produce symptoms such as seizures and stroke(Ali et al,2009). 
Cysts in the kidney can cause hematuria or flank pain, immune complex-mediated disease, 
glomerulonephritis leading to the nephrotic syndrome, and secondary amyloidosis (Gogus 
et al,2003; Gelman et al,2000) (Figure 2).  
           
Fig. 2. A,B: MRI T2W coronal and axial images show a heterogenous semisolid cyst hydatid 
lesion (Gharbi type 4, WHO CE4) with hyperintense cystic  areas located at the left kidney. 
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Bone involvement is rare (0.2-4%), affecting the spine in almost half of the cases. The other 
localizations are pelvis and long bones. The disease is usually silent until a complication 
such as paraplegia or pathologic fracture occurs. Many cases are diagnosed intraoperatively. 
Pre-operative diagnosis is based on radiological findings and serological assays 
(Papanikolaou,2008). 
Ocular cysts also occur(Schallenberg et al,2007). 
Cyst rupture is another severe complication of cyctic echinococosis. Acute hypersensitivity 
reactions including anaphylaxis, may be the principal manifestations of cyst rupture. Fever 
can be seen. Hypersensitivity reactions are related to the release of antigenic material and 
secondary immunologic reactions 
Calcification occurs mostly with hepatic cyst but can also be seen in pulmonary or bone 
cysts. It usually requires five to 10 years to develop. Total calcification of the cyst wall 
suggests that that the cyst may be nonviable. 
6.2 Clinics in Echinococcus multilocularis  
Alveolar echinococcosis is characterized by an initial asymptomatic incubation period of 5–
15 years and a subsequent chronic course. The infection may persist for years within an 
initial phase and might be detected by chance or during screening programmes. The most 
common presenting complaints include malaise, weight loss and right upper quadrant 
discomfort due to hepatomegaly. Later, severe hepatic dysfunction occurs and is often 
associated with portal hypertension. Cholestatic jaundice, cholangitis and the Budd-Chiari 
syndrome can also occur(Kern,2010). 
Alveolar echinococcosis is a rare chronic and progressive disease, which can involve mostly 
liver and in rare cases lung and brain. It devolops predominantly in the right lobe, from foci 
of a few millimetres to areas of 15–20 cm in diameter, sometimes with central necrosis. Giant 
lesions are reported occasionally (Yapici et al,2011). 
Rarely, parasitic cysts may cause compression and thrombosis of the hepatic venous outflow 
tract. It may present as portal hypertension and variceal upper gastrointestinal bleeding 
(Dulger et al,2010).  
Extrahepatic primary disease is very rare (1 percent of cases). Thirteen percent of cases 
present as multiorgan disease where metacestodes involve the lungs, spleen,bone or brain in 
addition to the liver. In patients with cerebral alveolar echinococcosis, neurological 
symptoms prevailed, such as headache, seizures, vomiting, blindness, left face numbness, 
aphasia, or ataxia(Kern,2010). 
Immunodeficiency, such as HIV or transplantation, may accelerate the manifestations of 
alveolar echinococcosis. If left untreated, mortalitiy is high( more than 90 percent of patients 
will die within 10 years of the onset of clinical symptoms, and virtually 100 percent by 15 
years). Since treatment with albendazole has been introduced, the prognosis has improved 
considerably 
In a recent study from France, where 362 patients with AE were evaluated. 83%of the 
patients were  presented with clinical patterns evocative either of a digestive or a hepatic 
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disorder. Other symptomatic patients presented with  clinical pictures, generally due to 
metastasis or extra-hepatic location of the parasite. Except for a few patients with 
particularly severe AE who died shortly after the diagnosis, most patients were treated 
using benzimidazoles and  their mortality tends to merge with that of the general French 
population, matched by sex, age, and calendar year (Piarroux et al,2011). 
7. Diagnosis 
7.1 Diagnosis of Echinococcus granulosus 
7.1.1 Routine laboratory tests  
Nonspecific leukopenia or thrombocytopenia, mild eosinophilia, and nonspecific liver 
function abnormalities may be detected, but are not diagnostic. Eosinophilia is seen in 15% 
of cases and generally occurs only if there is leakage of antigenic material. 
7.1.2 Imaging  
Computed tomography (CT) scanning, magnetic resonance imaging (MRI), and ultrasound 
are used to detect hydatid cysts and to evaluate their characteristics. Ultrasound is 
employed most widely because it is easy to perform and less expensive. 
Plain radiography may reveal calcification within a cyst, but cannot detect uncalcified cysts 
and is not the imaging technique of choice. 
7.1.2.1 Ultrasound  
US examination is the basis of CE diagnosis in abdominal locations, at both the individual 
and population levels (Macpherson and Milner, 2003). It has a sensitivity of approximately 
90 to 95 percennt. US may visualize cysts in liver or in other organs, including lung when 
cysts are peripherally located (El Fortia et al.2006). The most common appearance on 
ultrasound is an anechoic smooth, round cyst, which can be difficult to distinguish from a 
benign cyst. When the liver cyst contains membranes, mixed echoes will appear that can be 
confused with an abscess or neoplasm. Internal septations are due to daughter cysts. 
Pulmonary lesions may be single or multiple, usually do not calcify, rarely lead to daughter 
cyst formation, and may contain air if the cyst has ruptured. 
The ultrasonographic (US) appearance of hydatid cysts may vary. The cyst wall usually 
manifests as double echogenic lines separated by a hypoechogenic layer. Simple cysts do not 
demonstrate internal structures, although multiple echogenic foci due to hydatid sand may be 
seen within the lesion by repositioning the patient. The term "hydatid sand," reflects a complex 
image which consists predominantly of hooklets and scolexes from the protoscolices. This 
finding may be visible when shifting the patient's position during imaging. The echogenic foci 
quickly fall to the most dependent portion of the cavity without forming visible strata. This 
finding has been referred to as the snowstorm sign (Pedrosa et al,2000).  
US is the most sensitive modality for the detection of membranes, septa, and hydatid sand 
within the cyst. US also allows for the classification of the cyst(s) by biologic activity. Cyst 
may be active, transitional, or inactive. An inactive lesion include a collapsing, flattened 
elliptical cyst which means low pressure within the cyst, detachment of the germinal layer 
www.intechopen.com
 Zoonosis 334 
from the cyst wall, coarse echoes within the cyst, and calcification of the cyst Wall (Salama et 
al,1995; Suwan,1995). Detachment of the endocyst from the pericyst is probably related to 
decreasing intracystic pressure, degeneration, host response, trauma, or response to therapy. 
Complete detachment of the membranes inside the cyst has been referred to as the US water 
lily sign because of its resemblance to the radiographic water lily sign in pulmonary cysts. 
Cysts with a calcified rim may have an "eggshell" appearance.  
Multivesicular cysts manifest as well-defined fluid collections in a honeycomb pattern with 
multiple septa representing the walls of the daughter cysts. Daughter cysts appear as cysts 
within a cyst. The matrix represents hydatid fluid containing membranes of broken 
daughter vesicles, scolices, and hydatid sand. Membranes within the matrix can be seen as 
serpentine linear structures and this finding is highly specific for hydatid disease. 
When the matrix fills the cyst completely, a mixed echogenic pattern is created that mimics a 
solid mass. Daughter vesicles or membranes are very important images for differential 
diagnosis of the lesion. Cyst calcification usually occurs in the cyst wall, although internal 
calcification in the matrix may also be seen. When the cyst wall is heavily calcified, only the 
anterior portion of the wall is visualized and appears as a thick arch with a posterior 
concavity. Partial calcification of the cyst can not be assumed as the death of the parasite but 
densely calcified cysts are mostly inactive.  
There are some classification systems based upon ultrasound appearance: One is the Gharbi 
classification, which divides cysts into five types (Gharbi,1981). Type I cysts consist of pure 
fluid (Figure 3); type II have a fluid collection with a split wall; type III cysts contain 
daughter cysts (with or without degenerated solid material); type IV have a heterogeneous 
echo pattern (Figure 4); and type V have a calcified wall.  
In 1995, the WHO-IWGE developed a standardised classification that could be applied in all 
settings allowing grouping of the cysts into three relevant groups: active (CE1 and 2), 




Fig. 3. A: B-mode ultrasonography demonstrating an anechoic, smooth cyst located at the 
right lobe of the liver: Cyst Hydatid (Gharbi type 1, WHO; CE 1). The cyst wall manifests as 
double echogenic lines separated by a hypoechogenic layer (arrows). 
www.intechopen.com
 Echinococcosis 335 
 
 
Fig. 3. B: Cyst volume: 1386 cc. Arrows indicating cyst wall. 
 
Fig. 4. MRI T2W image shows a hyperintense heterogenous cyst hydatid (Gharbi Type 4, 
WHO CE 4) (arrows) located at right liver lobe. 
 
 
Table 1. Comparison of Gharbi’s and WHO-IWGE ultrasound classification. (Brunetti,2010) 
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WHOIWGE classification differs from Gharbi’s classification introduced in 1981 by adding a 
“cystic lesion” (CL) stage (undifferentiated), and by reversing the order of CE Types 2 and 3 . 
CE3 transitional cysts may be differentiated into CE3a (with detached endocyst) and CE3b 
(predominantly solid with daughter vesicles) ( Junghanss et al et al. 2008). CE1 and CE3a are 
early stages and CE4 andCE5 late stages. 
7.1.2.2 Computed tomography  
CT is indicated in cases in where US could not be used due to patient-related difficulties such 
as obesity, excessive intestinal gas, abdominal wall deformities, previous surgery or disease 
complications. It has a high sensitivity and specificity for hepatic hydatid disease (Figure 5). 
Intravenous administration of contrast material is not necessary unless complications are 
suspected, especially infection and communication with the biliary tree. CT is best in showing 
cyst wall calcification, cyst infection and peritoneal seeding( Ilica et al,2007). 
  
Fig. 5. A, B:  CT axial (A) and coronal (B) images show hyperdense calcified cyst hydatid 
(arrows) (Gharbi type 5, WHO CE 5) located at the left liver lobe. Another smaller 
hypodense cyst hydatid lesion (arrowhead) can be seen on the coronal plane. 
CT may show hepatic cystic lesion which includes many small round shaped cystic lesions 
that have a lower density of inner substance than the density of the inner substance of the 
mother cystic lesion. The presence of daughter cysts is a pathognomonic sign of the cystic 
hydatid nature, and these CT findings are thought to be specific for cystic echinococcosis in 
spite of the low appearance rate of 30%. (Ohnishi et al,2008) 
In one study, ultrasound performed better than CT in the investigation of the cyst wall, 
hydatid sand, daughter cysts, and splitting of the cyst wall, while CT was superior in 
detecting gas and minute calcifications within the cysts, in attenuation measurement, and in 
anatomic mapping. Detachment of the laminated membrane from the pericyst can be 
visualized as linear areas of increased attenuation within the cyst. Daughter vesicles 
manifest as round structures located peripherally within the mother cyst. 
Extrahepatic abdominal hydatid lesions have nearly identical imaging features, including 
the presence of cyst wall calcification, daughter cysts, and membrane detachment. The 
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combinations of radiologic and serologic tests especially in patients living in the endemic 
areas contribute to the diagnosis( Ohnishi et al,2008; Ilica et al,2007). 
7.1.2.3 Magnetic Resonance Imaging (MRI) 
MRI shows the characteristic low-signal-intensity rim of the hydatid cyst on T2-weighted 
images(Reiterova,2005). It probably represents the outer layer of the hydatid cyst (pericyst), 
which is rich in collagen and is generated by the host. Although cyst wall calcification is 
more clearly depicted at CT, MR imaging is superior in demonstrating irregularities of the 
rim. These irregularities probably represent incipient detachment of the membranes (Davilo 
et al,1990) (Figure 6).   
   
Fig. 6. A,B: MRI T2W (A) and Heavy T2W (B) images show  hypointense cyst hydatid lesion 
with  a hyperintense split wall  located at the left liver lobe (Gharbi Type 2, WHO C3a). 
According to WHO, computed tomography and magnetic resonance imaging, and if 
possible cholangiopancreatography (MRCP) are indicated in 
1. Subdiaphragmatic location,  
2. Disseminated disease,  
3. Extraabdominal location,  
4. In complicated cysts (abscess, cysto-biliary fistulae) and 
5. Pre-surgical evaluation.  
Whenever possible, MR imaging should be preferred to CT due to better visualization of 
liquid areas within the matrix (Hosch et al, 2008). 
Other imaging techniques such as cholangiography may be indicated to diagnose biliary 
involvement, particularly in patients with cholestatic jaundice. ERCP can be performed in 
patients with liver cysts prior to intervention.  
7.1.3 Serology  
Sensitivity of serum antibody detection using indirect hemagglutination, enzyme-linked 
immunosorbent assay (ELISA), or latex agglutination, with hydatid cyst fluid antigens, 
ranges between 85 and 98% for liver cysts, 50–60% for lung cysts and 90–100% for multiple 
organ cysts (Siracusano and Bruschi, 2006; Ito and Craig, 2003; Siles-Lucas and Gottstein, 
2001). Detection of circulating E. granulosus antigens in serum is less sensitive than antibody 
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detection, which remains the method of choice. Neverthless, due to the cross-reactions with 
other cestode infections (E. multilocularis and Taenia solium), some other helminth diseases, 
malignancies, liver cirrhosis and presence of anti-P1 antibodies, the specificity of all tests are 
limited and confirmatory tests must be used (arc-5 test; Antigen B (AgB) 8 kDa/12 kDa 
subunits or EgAgB8/1 immunoblotting) in dubious cases (Siracusano and Bruschi, 2006; Ito 
and Craig, 2003.  
Detection of parasite-specific IgE or IgG4 has no significant diagnostic advantage since these 
antibodies remain in serum for long periods following surgical removal or effective drug 
treatment of cysts, or even if the infection self-cures. Bulut et al showed that after surgical 
treatment of the disease, total IgE levels in the sera of the patients decreased to normal six 
months after surgery. Specific IgE against echinococcal antigens decreased one year after 
operation, but serum levels were still significantly high. There were no changes in the levels of 
anti-Echinococcus IgG and total IgG in follow-up period. Additionally, other parameters, such 
as IgA, IgM, C3 and C4, were not affected (Bulut et al, 2001). There may be also false negative 
results with varying frequency depending upon the site of the lesion and the cyst's integrity 
and viability. Antigen-antibody complexes that remove all antibodies may lead to false 
negative reactions. Thus, a negative serologic test generally does not rule out echinococcosis.  
In fact ELISA using crude hydatid cyst fluid has a high sensitivity (over 95%) but its 
specificity is often unsatisfactory. If purified antigens like antigen B or other techniques such 
as immunoblot analysis, detection of immunoglobulin G4 (IgG4) antibodies and 
immunoelectropheresis are used, specificity is improved but average sensitivity is much 
lower. Furthermore, it should be remembered that approximately 10 to 20% of patients with 
hepatic cysts and about 40% with pulmonary cysts do not produce detectable specific serum 
antibodies (IgG) and therefore give false-negative results. Cysts in the brain, bone, or eye 
and calcified cysts often induce no or low antibody responses. Children and pregnant 
women more frequently have negative serology than other patient populations. Neverthless,  
immunoblotting may be used as a first-line test and is best for differential diagnosis (Akisu 
et al,2006; Eckert &dePlazes,2004) 
7.1.4 Cyst aspiration or biopsy  
Microscope examination of protoscoleces after cyst fluid aspiration using vital staining gives 
evidence for the parasitic nature and viability of a cyst (WHO/OIE, 2001). Detection of 
parasitic antigens gives no indication of viability. Presence of calcification is not reliable as 
an indicator of non-viability: more frequent in CE4 and CE5, it may be observed at all stages 
(Hosch et al, 2007).  
MRS may be used to examine cyst fluid ex vivo and prepare detailed quantitative metabolite 
profiles, enabling a multivariate metabolomics approach to cyst staging. (Hosch et al., 2008). 
In vivo evaluation of cyst viability has already been performed using MR spectroscopy in 
cysts that do not move with respiration such as brain cysts. In a patient with hydatid disease 
of the brain and on albendazole treatment, Seckin et al. performed MRS before the medical 
therapy was begun, which revealed the typical findings of a hydatid cyst with resonance of 
alanine, acetate, and succinate that were specific for hydatid disease, and additional 
nonspecific lactate peaks with an additional small peak of choline. Two sequential MRS 
imaging revealed a prominent decrease of the succinate and acetate resonance, accompanied 
by a smaller decline of the alanine resonance progressively, correlated with the conventional 
MRI findings of the cyst, which had a smaller size with blurred margins in the meantime. 
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After 5 months of medical treatment, the cyst had completely disappeared. The patient has 
been monitored for 5 years and remains well without recurrence. The author concluded that 
changes in the metabolic profile of the cyst, especially those regarding succinate and acetate 
may represent the efficacy of the medical treatment.(Seckin et al, 2008) and might become 
possible for other locations in the future (Hosch et al, 2008). 
Percutaneous aspiration of an active cysts reveal clear watery fluid containing scolices and 
have elevated pressure, whereas inactive cysts exhibit cloudy fluid without detectable 
scolices and do not have elevated pressure (Salama et al,1995). Percutaneous aspiration of 
liver cyst contents is associated with very low rates of complications, but this method of 
diagnosis is generally reserved for situations when other diagnostic methods are 
inconclusive because of the potential for anaphylaxis and secondary spread of the infection 
(Gargouri et al,1990; Khuroo et al,1993; Filice et al,1990; Giorgio et al,1992).To prevent 
secondary echinococcosis if a hydatid cyst is punctured, chemotherapy with albendazole is 
recommended for 4 days before the procedure. Chemotherapy should be continued for at 
least 1 month a fter puncturing a lesion that was diagnosed as an E. granulosus cyst even 
after its immediate surgical removal Increasingly, cyst puncture also is performed as a 
therapeutic measure.  
According to WHO, the diagnostic criterias for cystic echinococcus are: 
1. Typical organ lesion(s) detected by imaging techniques (e.g. US, CT-scan, plain film 
radiography, MR imaging 
2. Specific serum antibodies assessed by high-sensitivity serological tests, confirmed by a 
separate high specificity serological test. 
3. Histopathology or parasitology compatible with cystic echinococcosis (e.g. direct 
visualization of the protoscolex hooklets in cyst fluid). 
4. Detection of pathognomonic macroscopic morphology of cyst(s) in surgical specimens. 
WHO defines the possible versus probable versus confirmed cases as follows: 
Possible case: Any patient with a clinical or epidemiological history, and imaging findings 
or serology positive for CE. 
Probabale case: Any patient with the combination of clinical history, epidemiological 
history, imaging findings and serology positive for CE on two tests 
Confirmed case: The above, plus either 
1. Demonstration of proto scoleces or their components, using direct microscopy or 
molecular biology, in the cyst contents aspirated by percutaneous puncture or at 
surgery, or  
2. Changes in US appearance, e. g. Detachment of the endocyst in a CE1 cyst, thus moving 
to a CE3a stage, or solidification of a CE2 or CE3b, thus changing to a CE4 stage, after 
administration of ABZ (at least 3 months) or spontaneous 
7.2 Diagnosis of Echinococcus multilocularis  
7.2.1 Routine laboratory tests  
Nonspecific leukopenia or thrombocytopenia, mild eosinophilia, and nonspecific liver 
function abnormalities may be detected, but are not diagnostic. Hypergammaglobulinemia 
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and elevated serum IgE levels are present in more than 50 percent of cases. In a recent study, 
absence of eosinophils in the peritoneal cavity and a low number of such cells in the blood 
of infected animals was observed and this was related to metacestode antigens (in vitro 
generated vesicle fluid and E/S products) that  were able to proteolytically digest eotaxin.  
Proteolysis of eotaxin was, thus, dose-dependent and proportional to the time of incubation 
with the metacestode antigens. Absent eosinophils, thus, may be a part of a series of events 
that maintain a low level of inflammation displayed within the peritoneal cavity of 
experimentally infected mice (Mejri&Gottstein, 2009). 
7.2.2 Imaging  
7.2.2.1 Ultrasound 
US examination is the basis of AE diagnosis in abdominal locations, at the individual and 
population levels, but needs an experienced examiner (Bartholomot et al., 2002; Romig et 
al.,1999). The lesion resembles a tumor, but the patient's overall condition is usually better 
than would be expected for a malignancy. 
Typical findings (70% of cases) include  
1. Juxtaposition of hyper- and hypoechogenic areas in a pseudo-tumour with irregular 
limits and scattered calcification and  
2. Pseudo-cystic appearances due to a large area of central necrosis surrounded by an 
irregular hyperechogenic ring.  
Less typical features (30% of cases) include 
1. 1- Hamangioma-like hyperechogenic nodules as the initial lesion and  
2. 2- A small calcified lesion due either to a dead or a smallsized developing parasite 
(Bresson-Hadni et al., 2000, 2006).  
US with colour Doppler provides information on biliary and vascular involvement. 
7.2.2.2 CT and MRI 
CT gives an anatomical and morphological characterization of lesions and best depicts the 
characteristic pattern of calcification (WHO/OIE, 2001). In cases of diagnostic uncertainty, 
MR imaging may show the multivesicular morphology of the lesions, thereby supporting 
the diagnosis (Bresson-Hadni et al., 2006) It is the best technique to show invasions to 
adjacent structures. For pre-operative evaluation, MRCP has replaced percutaneous 
cholangiography to study the relationship between the AE lesion and the biliary tree 
(Bresson-Hadni et al., 2006). Initial radiological examination to exclude pulmonary and 
cerebral AE is recommended.  
Common CT and MR imaging findings of cerebral lesion seen with E. multilocularis is a well-
defined multiseptated mass consisting of solid and cystic components with calcification in 
the solid portion (Bukte et al,2004). 
The characteristic radiological findings of pulmonary alveolar hydatid disease include 
intersegmental distribution involving the segmental veins. Alveolar hydatid disease 
probably spreads via emboli, in a manner similar to that of metastatic neoplasms.The 
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absence of marked  retraction of adjacent organs such as pleura, bronchus and pulmonary 
vessels seems to be characteristic of pulmonary alveolar hydatid disease caused by E. 
multilocularis (Ohsaki et al,2007). 
7.2.3 Serology  
Serology can also be helpful in the diagnosis of E. multilocularis infection. Immunodiagnostic 
tests for primary diagnosis or confirmation of imaging results are more reliable in the 
diagnosis of AE than of CE since more specific antigens are available. For example, the 
Em2plus-ELISA, using a mixture of affinity-purified E. multilocularis metacestode antigens 
(Em2-antigen) and a recombinant antigen (EmII/3-10), exhibited a diagnostic sensitivity of 
97% in patients with confirmed AE and an overall specificity of 99% for infections due to 
other helminths. The use of purified and/or recombinant, or in vitro-produced E. 
multilocularis antigens (Em2, Em2+, Em18, etc) has a high diagnostic sensitivity of 90–100%, 
with a specificity of 95–100%. Most of the purified antigens allow discrimination between 
AE and CE in 80–95% of cases. Immunoblotting tests may be used for confirmation or as a 
firstline investigation if easily available. Serology usually remains positive indefinitely in 
patients receiving chemotherapy, yet may become negative within a few years following 
complete surgical resection. Clinical recurrence is often associated with rising serologic 
titers. IgG1 and IgG4 antibodies are the most sensitive isotypes for monitoring the success of 
therapy  (Schantz et al,1983; Ito et al,1995; Brunetti et al,2010) 
For AE screening, a combined approach using US and serology discriminates different 
infection status among seropositive individuals:  
1. Patients with active hepatic lesions,  
2. Individuals presenting with fully calcified lesions and  
3. Individuals presenting with no detectable lesion at all.  
The latter two variants refer to persons exposed to infection but in whom the parasite has 
not become established or does not progress (Vuitton et al., 2006). 
According to WHO, the diagnostic criteria for alveolar echinococcus are: 
1. Typical organ lesions detected by imaging techniques (e.g.abdominal US, CT, MR). 
2. Detection of Echinococcus spp. specific serum antibodies by highsensitivity serological 
tests and confirmed by a high specificity serological test. 
3. Histopathology compatible with AE. 
4. Detection of E. multilocularis nucleic acid sequence(s) in a clinical specimen. 
WHO defines the possible versus probable versus confirmed cases as follows: 
Possible case: Any patient with clinical and epidemiological history and imaging findings or 
serology positive for AE. 
Probable case: Any patient with clinical and epidemiological history, and imaging findings 
and serology positive for AE with two tests. 
Confirmed test: The above, plus (1) histopathology compatible with AE and/or (2) detection 
of E. multilocularis nucleic acid sequence(s) in a clinical specimen 
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8. Treatment  
8.1 Treatment of Echinococcus granulosus 
A number of surgical and non-surgical options exist to treat cystic echinococcosis of the 
liver. Pre- and post-intervention chemotherapy with albendazole or mebendazole reduces 
the risk of disease recurrence and intraperitoneal seeding of infection that may develop by 
cyst rupture and spillage occurring spontaneously or during surgery or needle drainage. 
PAIR appears to be more effective treatment method with lower rates of major and minor 
complications, mortality, and disease recurrence.  Hospitalization period is also shorter 
compared to patients treated surgically. PAIR is a safe and effective procedure of choice for 
patients with hepatic echinococcosis, and perhaps other anatomic sites of infection such as 
lung, peritoneum, kidney, and other viscera when the medication are ineffective.  Surgery 
should be reserved for patients with hydatid cysts refractory to PAIR because of secondary 
bacterial infection or for those with difficult-to-manage cyst-biliary communication or 
obstruction(Smego et al,2005). 
8.1.1 Open surgery  
Indications for surgery should be evaluated carefully before making decision. Open surgery 
is the first treatment choice for complicated cysts, and it is also an option for complete 
removal of the parasite in patients who can tolerate surgery and who have cysts in amenable 
locations.  According to WHO-IWGE experts, the indications for surgery are: 
1. Removal of large CE2-CE3b cysts with multiple daughter vesicles, 
2. Single liver cysts, situated superficially, that may rupture spontaneously or as a result 
of trauma when PTs are not available, 
3. Infected cysts, again, when PTs are not available,  
4. Cysts communicating with the biliary tree (as alternative to PT) and 
5. Cysts exerting pressure on adjacent vital organs(Brunetti et al, 2010). 
Surgery is also preferred for large liver cysts (diameter >10 cm, especially if associated with 
multiple daughter cysts); superficially located single liver cysts; complicated cysts such as 
those accompanied by infection, compression, or obstruction; or cysts in the lung, kidney, 
bone, brain, or other organs (Dervenis et al,2005; Safioleas et al,2006; Junghanss et al,2008). 
Contraindications of surgery are (Brunetti et al, 2010): 
1. Patients to whom general contraindication for surgery apply, 
2. Inactive asymptomatic cyst 
3. Difficult to Access cyst 
4. Very small cyst  
8.1.1.1 Surgical techniques  
Total removal of the cyst is usually described as “pericystectomy.” “Closed total 
pericystectomy” removes the cyst without opening it, and “open total pericystectomy” 
sterilizes the metacestode with protoscolicidal agents, evacuates the contents of the cyst, then 
removes the pericystic tissue. There is a cleavage plane between the inner layer of the host’s 
reaction facing towards the parasite and the outer layer, or adventitia which limits the damage 
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to liver parenchyma when dissecting around the cyst and allows safer removal of the cyst 
(Peng et al. 2002). All these operations can be named as total cystectomy. Partial cystectomy, in 
which the cyst content is sterilized and removed after opening, with the pericyst partially 
resected, is especially suited for endemic areas where the operations are performed by general 
surgeons. But the risk of secondary echinococcosis from protoscolex dissemination is higher 
than with total pericystectomy or total cystectomy( Brunetti et al, 2010) .  
The main goals of surgical therapy include: 
1. Evacuation of the cyst while avoiding spillage of its contents,  
2. Neutralization of the cyst, and  
3. Obliteration of the residual cavity (Safioleas et al,2006). 
Adequate drainage and obliteration of the remaining cavity is a necessary procedure to 
minimize the possibility of serum or blood accumulation or liver abscess formation. 
Although conservative surgical procedures are considered simpler and safer to perform, the 
rate of postoperative complications such as biliary fistula, residual cavity and recurrence, 
and cavity suppuration has been reported to be about 35%. On the other hand, radical 
surgery can be performed with low risk of recurrence (3.2%).(Aydin et al. 2008).   
The treatment modalities for liver cysts include total pericystectomy, partial hepatic 
resection and more conservative procedures including simple-closure tube drainage and 
cavity management via capitonnage (obliteration of residual cavity after cyst extrusion 
using deep purse-string suturing). Marsupialization (now rarely done), omentoplasty, 
introflexion or internal drainage are not commonly performed. 
The surgical options for lung cysts include lobectomy, wedge resection, pericystectomy, 
intact endocystectomy, and capitonnage. In a large study of 842 patients followed for 3 to 20 
years, a recurrence rate of 1.9 percent was noted after intact endocystectomies(Qian,1998). 
Any effort made to avoid fluid spillage is recommended, including protection of peritoneal 
tissues and organs with protoscolicide-soaked surgical drapes and injection of 
protoscolicide into the cyst before opening(Brunetti et al, 2010).  Twenty percent hypertonic 
saline is recommended, and should be in contact with the germinal layer for at least 15 
minutes. (WHO/OIE, 2001).  In order to reduce the risk of chemically-induced sclerosing 
cholangitis, its use should be avoided when communication between the cyst and the bile 
ducts is found. Formalin, which frequently was used for this purpose in the past, is no 
longer recommended because of an increased risk of sclerosing cholangitis. 
Ivermectin, praziquantel (PZQ) and BMZ solutions have been used as protoscolicodal 
agents however, they should be further studied in humans for efficacy and safety (Bygott 
and Chiodini, 2009; Dziri et al., 2009). Peri-operative BMZ may reduce cyst pressure and 
decrease the risk of secondary CE. The length of administration usually ranges between 1 
day before and 1 month after surgery but has never been formally evaluated.  
8.1.1.2 Cysto-Biliary fistulas 
In clinically asymptomatic patients, cyst diameter can be a clue for the presence of  cysto-
biliary fistulas.  With a cyst diameter of 7.5cm as a cut-off point, a 79%, likelihood to find a 
cysto-biliary fistula was calculated (Aydin et al. 2008). When this complication is detected, 
www.intechopen.com
 Zoonosis 344 
sphincterotomy alone is not an adequate treatment. Most communications can be managed 
with suture during surgery. However, biliary-intestinal anastomosis or liver resection are 
sometimes necessary. It is also advisable to do an ERCP pre-PAIR and to perform 
postaspiration imaging of the cyst using contrast to rule out possible communication with 
the biliary tree. 
8.1.1.3 Outcome  
Complications of surgery include infection of the residual cavity, intraabdominal abscesses, 
anaphylactic reactions, spillage of parasite material leading to secondary echinococcosis, 
biliary fistulation, and sclerosing cholangitis. Surgical mortality is usually 0.5 to 4 percent 
for the first intervention, but increases with repeated interventions and with inadequate 
experience or operative facilities. Surgery is not the optimal treatment for complicated liver 
CE and disseminated CE (Dziri et al., 2004). 
8.1.2 Laparoscopy  
Laparoscopic treatment of liver echinococcosis has become increasingly popular, most 
suitable treatment option for the cases with anteriorly located hepatic cysts; have high 
success, low complication and low recurrence rates(Bickel et al,1998). Laparoscopic 
treatment includes partial or total pericystectomy and cyst drainage with omentoplasty. 
Disadvantage of laparoscopy is the lack of precautionary measures to prevent spillage 
under the high intraabdominal pressures caused by pneumoperitoneum(Dervenis et 
al,2005). Allergic reactions are more common in laparoscopic interventions due to peritoneal 
spillage, although length of stay is generally shorter and morbidity rates lower than for open 
procedures. Laparoscopic treatment is not suitable for deep intraparenchymal cysts or 
posterior cysts situated close to the vena cava, more than three cysts with thick and calcified 
walls (Chowbey et al,2003; Ertem et al,2002; Seven et al,2000). 
8.1.3 Percutaneous treatments  
Percutaneous treatments can broadly be divided into:  
1. Those aiming at the destruction of the germinal layer (puncture, aspiration, injection 
and reaspiration, or PAIR) and  
2. Those aiming at the evacuation of the entire endocyst (also known as Modified 
Catheterization Techniques). (Brunetti et al,2010) 
8.1.3.1 PAIR procedure  
Puncture, aspiration, injection and reaspiration (PAIR) is a percutaneous cyst puncture 
procedure performed under ultrasound or CT guidance followed by aspiration of 
substantial amounts of cyst fluid and injection of a protoscolicidal agent into the cyst cavity.  
PAIR confirms the diagnosis and removes parasitic material. It is minimally invasive, less 
risky and usually less expensive than surgery (Smego et al., 2003). 
Protoscolicides used in PAIR are mainly 20% NaCl and 95% ethanol. Transhepatic cyst 
puncture prevents peritoneal protoscolex spillage. The cyst is then reaspirated after a period 
of at least 15 minutes. Prophylaxis with ABZ 4 h before and 1 month after PAIR is 
mandatory (WHO-IWGE, 2003a,b). 
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PAIR is a minimally invasive technique used in the treatment of cysts in the liver and other 
abdominal locations (WHO-IWGE, 2003a,b). It is indicated for inoperable patients and those 
who refuse surgery, in cases of relapse after surgery or failure to respond to BMZ alone. Best 
results with PAIR + BMZ are achieved in >5cm CE1 and CE3a cysts and suggested as first-
line treatment (Khuroo et al., 1993). PAIR is contraindicated for CE2 and CE3b, for CE4 and 
CE5, and for lung cysts. The presence of biliary fistulae is also a contraindication for PAIR 
because of protoscolicide use. It should not be used in patients with inaccessible cysts, 
superficially located liver cysts where there is a risk of spillage into the abdominal cavity, 
cysts with nondrainable solid material or echogenic foci and inactive or calcified cysts. 
The potential risks of this procedure include anaphylaxis, secondary echinococcosis,  
hemorrhage, infection, chemical sclerosing cholangitis, and biliary fistulas. PAIR should 
only be performed by experienced physicians with drugs and resuscitation equipment to 
manage anaphylactic shock at hand and a surgical back-up team. The WHO panel 
concluded that the use of PAIR is widespread and increasing in all areas where cystic 
hydatid disease is a problem and PAIR appears to be a safe and effective therapeutic tool.  
In a study from Bulgaria, PAIR was performed in 230 patients with 348 echinococcal cysts. 
At 12-month follow-up, 77.6% of the cysts, all cystic echinococcosis (CE) 1 and CE3a cysts 
according to the World Health Organization Informal Working Group classification, showed 
various degrees of obliteration. In 11.5% of cysts, all of which were > 10 cm-type CE1, a 
significant amount of fluid persisted, and they were punctured again. Of those, 16 (4.6%) 
contained protoscolices and were treated by a second PAIR. The remaining 24 (6.9%) cysts 
were treated by simple aspiration or drainage. No significant reduction in size and no 
changes in the structure were observed in 10.9% of cysts, all of which were classified as CE2 
or CE3b. Complications developed in 25.2% of patients, including severe anaphylactic 
reaction in two (0.9%) patients(Golemanov et al,2011).  
Percutanous treatment of hydatid cysts in pregnancy is also an efficient and safe procedure 
in cases where percutaneous treatment is indicated (Ustunsoz et al,2008).  
Ustunsoz has reported six pregnant patients (age range 19-28 years; mean age 23 years) with 
six hepatic hydatid cysts who underwent percutaneous treatment without albendazole 
prophylaxis. PAIR technique was used to treat the cysts. They used hypertonic saline 
solution as cytotoxic agent and followed-up patients mainly by sonography every 2 weeks 
during pregnancy, every third month post-partum for the first year, every 6 months for the 
second year, and once a year thereafter. Average hydatid cyst volume which was 2,145 ml 
before treatment was reduced to 145 ml post-treatment at the time of delivery. A 
cystobiliary fistula was found in one patient and a percutaneous catheter was placed into 
the postresidual cavity and a nasobiliary catheter was placed into the common bile duct 
after syphincterotomy. The fistula was closed in 2 weeks. This patient has a follow-up time 
of 1 year so far without any problem. No mortality, morbidity, fetal loss, abdominal 
dissemination, or tract seeding was observed among these cases. 
Another paper from Turkey reported a single-center experience comparing surgery, 
laparoscopic surgery, and percutaneous treatments in 355 patients with 510 hydatid cysts of 
the liver over a period of 10 years. There were two postoperative deaths (1.08%) in the open 
surgery group. Biliary leakage was observed in 28 patients treated with open surgery, in 10 
patients after PT, and in 2 after laparoscopic treatment. Recurrence rates were 16.2%, 3.3%, 
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and 3.5% after open surgery, laparoscopic surgery, and percutaneous treatment, 
respectively. They stated that characteristics of the cyst, presence of cystobiliary 
communications, and the availability of a multidisciplinary team are the factors affecting the 
results and concluded that PAIR is effective and safe (Yagcı et al,2005). 
Gabal et al. performed a modified PAIR techique for percutaneous high risk hydatid cysts. 
In this method, they used a coaxial catheter system to achieve concomitant evacuation of 
cyst contents while infusing scolicidal agent. Hypertonic saline was used to wash out cyst 
contents and to kill protoscolices which was followed by injection of a sclerosant (ethyl 
alcohol 95%) into the residual cyst cavity to prevent formation of a cyst collection after the 
procedure. 17 cysts in 14 patients were successfully aspirated. They found gradual decrease 
in cyst size (17 cysts, 100%), thickening and irregularity of the cyst wall due to separation of 
endocyst from pericyst (7 cysts, 41%), development of a heterogeneous appearance of the 
cyst components (8 cysts, 47%) and development of pseudotumor (2 cysts, 12%). They 
concluded that  modified PAIR technique is a reliable method for percutaneous treatment of 
risky and symptomatic hydatid cysts (Gabal et al, 2005). 
8.1.3.2 Other percutaneous treatments  
Modified Catheterization Techniques are reserved for cysts that are difficult to drain or for 
cysts that tend to relapse after PAIR. These procedures aim to remove the entire endocyst 
and daughter cysts from the cyst cavity using large-bore catheters and cutting devices 
together with an aspiration apparatus. Among more than 1000 patients, rates of short- and 
medium-term success are satisfactory with minimal complications. These techniques have 
also been successfully employed for CE2 cysts located outside the abdomen (Akhan et al., 
2007). However, long-term follow-up of patients is unavailable, and the procedure should 
be done with caution. ( Brunetti et al,2010) 
8.1.4 Antiparasitic drug treatment 
Benzimidazoles (BMZ) inhibit the assembly of tubulin into microtubules, thus impairing 
glucose absorption through the wall of the hydatid parasite. This causes glycogen depletion 
and degeneration of the endoplasmic reticulum and mitochondria of the germinal layer of 
the metacestode, and results in an increase in lysosomes and subsequent cellular death. 
WHO recommendations state that medical therapy should be used for (Brunetti et al,2010): 
1. 1-Inoperable patients with liver or lung CE, 
2. 2-Patients with multiple cysts in two or more organs,  
3. 3-Peritoneal cysts, 
4. 4-Small (<5 cm) CE1 and CE3a cysts in the liver and lung  
5. 5-Prevention of  recurrence following surgery or PAIR  
According to WHO-IWGE experts, the contraindications for benzimidazoles are: 
1. 1-Cysts at risk of rupture 
2. 2-In early pregnancy 
Adverse effects of benzimidazoles include hepatotoxicity, leucopenia, thrombocytopenia 
and alopecia, so benzimidazoles must be used with caution in patients with chronic hepatic 
disease and should be avoided in those with bone-marrow depression. Inactive or calcified 
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asymptomatic cysts should not be treated unless they are complicated. BMZ alone are not 
effective in large cysts (over 10 cm), as their effect is extremely slow in cysts with large 
volumes of fluid . 
BMZ can be used in patients of any age. However, there is little experience with children 
under-6 years old; it is less limited by the patient’s status than surgery. The cure rate after a 
treatment period of 3-6 months with standart doses is 30%. Stojkovic et al. collected and 
analysed data from 711 treated patients with 1,308 cysts from six centres (five countries). 
Analysis was restricted to 1,159 liver and peritoneal cysts. They evaluated the importance of 
cyst stage and size in determining response to treatment They found that 1-2 y after 
initiation of benzimidazole treatment 50%-75% of active C1 cysts were classified as 
inactive/disappeared compared to 30%-55% of CE2 and CE3 cysts. They showed that 50%-
60% of cysts <6 cm responded to treatment after 1-2 y compared to 25%-50% of cysts >6 cm. 
However, 25% of cysts reverted to active status within 1.5 to 2 y after having initially 
responded and multiple relapses were observed; after the second and third treatment 60% of 
cysts relapsed within 2 years. (Stojkovic et al., 2009). 
8.1.4.1 Mebendazole  
It is the first benzimidazole agent tested against Echinococcus. The usual dosage is 40 to 50 
mg/kg per day, given in three divided doses with fat-rich meals. Maximal daily dose that 
can be given is 6 g. Therapy is usually indicated for at least three to six months. It is used if 
albendazole is not available or not tolerated. 
8.1.4.2 Albendazole  
Albendazole is currently the drug of choice to treat CE, either alone or together with PT. 
Given orally, at a dosage of 10–15 mg/kg/day, in two divided doses, with a fat-rich meal to 
increase its bioavailability. The hepatic metabolite of albendazole, albendazole sulfoxide, is 
also active against the parasite. Because of safety concern, albendazole was administered 
intermittently in four week courses, followed by an interval of two drug-free weeks but 
today it is recognised that continuous therapy does not increase the risk of side effects, and 
efficacy may be improved. 
In cases of preoperative treatment with albendazole, the results were in favor of the 3-month 
treatment while even the 1-month treatment was associated with improved effectiveness 
compared to no treatment.( Gil-Grande  et al,1993) Wen H et al and Aktan et al also 
performed prospective controlled trials that showed that 4-month cyclic (30 days on-therapy 
and 10 days off-therapy) and 3-week continuous preoperative treatment with albendazole, 
respectively, resulted to fewer viable cysts at the time of operation compared to no 
treatment. In a recent study, Stankovic et al reported statistically fewer viable protoscolices 
at the time of surgery for patients that received 3 weeks preoperative treatment with 
albendazole compared to those that received no preoperative treatment.(Wen et al,1994; 
Aktan et al,1996; Stankovic et al,2005) 
8.1.4.3 Flubendazole 
Flubendazole is another benzimidazole drug, which has been evaluated for CE treatment in 
both mice and men. Flubendazole has shown poor in vivo efficacy against CE in humans 
and mice. However, flubendazole causes marked in vitro damage on E. granulosus 
protoscoleces (Ceballos et al,2010). In a study by Ceballos et al, pharmacological 
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performance of the benzimidazole compounds flubendazole (FLBZ) and albendazole (ABZ) 
were evaluated. And they stated that flubendazole offers a great potential to become a drug 
of choice in the treatment of cystic echinococcosis(Ceballos et al,2011) 
8.1.4.4 Praziquantel 
This isoquinoline has been shown to have effective protoscolicidal activity, and may be 
more effective than albendazole in vitro. It can be used alone or in combination with 
albendazole. The dose of praziquantel is 40 mg/kg once a week or 25 mg/kg orally each 
day. Praziquantel increases serum concentrations of albendazole sulfoxide fourfold so 
combination of the two drugs seems more effective in killing protoscoleces than any 
alone(McManus et al,2003). It usually is well tolerated but occasionally causes headache, 
nausea or abdominal discomfort. However, the efficacy of praziquantel has varied in clinical 
studies, and its role in primary chemotherapy has not been clearly defined(Wen et al,1993). 
In a study of Mohamed et al. 41 patients with hepatic hydatid cysts were treated with either 
albendazole alone or in combination with praziquantel. Albendazole alone resulted in the 
complete disappearance of the cyst in 36 percent of subjects with treatment periods ranging 
from six months to two years, while the combination led to the complete disappearance of 
cysts in 47 percent after only two to six months of drug therapy (Mohamed et al,1998). In 
another study Cobo showed that in a patient cohort with intraabdominal hydatidosis, 
significantly greater number of patients treated preoperatively with albendazole and 
praziquantel had nonviable protoscolices at the time of surgery compared to patients 
receiving albendazole alone, at doses of both 10 mg/kg/day and 20 mg/kg/day. (Cobo et 
al,1998; Smego et al, 2005) 
8.1.4.5 Problems with chemotherapy  
Low penetrate of the drugs through the tissue barriers to reach inner compartments of the 
metacestode is an important problem in clinical practice. Manterola et al. studied the 
plasmatic and intracystal concentrations of albendazole sulfoxide (AS) and correlated them 
with the viability of the scolices in patients surgically treated for hepatic hydatid cysts that 
received albendazole preoperatively, as an indirect way of evaluating the scolicide efficacy 
of the drug. The patients were given 10 mg/kg/day of albendazole for 4 days prior to the 
surgery. Intraoperative samples of venous blood and hydatid fluid were taken, in which the 
plasmatic concentration and intracystal concentration of AS were measured by means of 
high-performance liquid chromatography. They found that there was no association 
between intracystal levels of AS and the viability of the scolices and concluded that 
albendazole is ineffective as a scolicidal agent administered preoperatively for 4 days 
(Manterola et al,2005).  
Since the intracystic concentration of albendazole is not correlated with the efficacy of the 
drug, duration of therapy may be an important issue.  
8.1.4.6 Outcome  
Albendazole is the drug of choice fo the treatment of CE. Studies that have directly 
compared mebendazole and albendazole have shown that mebendazole leads to an 
improvement in radiologic appearance in approximately 50 to 60 percent of patients, while 
75 to 85 percent of patients show a response to albendazole (Horton,1997; Teggi et al,1993; 
Todorov et al,1992).  The duration of treatment is shorter than mebendazole with a better 
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response rate. The results of chemotherapy are affected by cyst characteristics such as size, 
age and location, as well as by host characteristics (El-On,2003). 
8.1.5 Management of cysts in extra-hepatic sites 
The frequency of CE in extra-hepatic site is very low, and WHO recommendations for 
treatment is as follows: 
8.1.5.1 Lung 
The presentation of pulmonary CE varies widely, making a uniform treatment 
recommendation impossible. BMZ used alone showed good efficacy on small, 
uncomplicated lung cysts but should be avoided pre-operatively in larger lung cysts. 
Surgery aims at removing the parasite and treating associated pathology. It should be as 
conservative as possible. Radical procedures are required for extended parenchymal 
involvement, severe pulmonary suppuration, and complications (Isitmangil et al. 2002). 
8.1.5.2 Bone 
Bone involvement accounts for 0.5–2% of the total number of cases and is potentially the 
most debilitating form of CE. The most effective treatment is radical resection of the affected 
bone (Zlitni et al., 2001). Surgical procedures can be repeated because of the recurrences, and 
some serious complications such as spinal involvement, fistulae, acute and chronic 
osteomyelitis, have an extremely poor prognosis. When the hip is involved, broad resections 
should be carried out, with the implantation of a prosthetic hip absolutely contraindicated. 
CE in bone is less sensitive to ABZ than cysts at other sites and high dosage and long-term 
administration (years) are indicated( Brunetti et al,2010). 
8.1.5.3 Heart 
Cardiac involvement accounts for 0.5–2% of total cases with 10% of cases showing various 
symptoms. Surgery is the treatment of choice (Thameur et al., 2001). Venous filters are used 
to prevent dissemination. If complete removal of the cysts is possible, the prognosis is good, 
with a low rate of recurrence. 
8.1.5.4 Disseminated disease 
When cysts are widespread, usually after cyst rupture, spontaneously or during surgery, a 
surgical approach is often impractical. If the cysts are very large or located in or near vital 
organs the treatment should be combined surgery and ABZ, despite its palliative nature. 
However, medical treatment alone with ABZ, maintained for an indefinite length of time, is 
the only option available in most cases, with an acceptable response (reduction in the 
number and/or size of lesions) (Chawla et al., 2003). Discontinuation is often associated 
with recurrence. 
8.1.6 Watch and wait  
The idea of leaving certain cyst types untreated and just monitoring them over time is a 
logical consequence because of two main findings:  
1. A good proportion of cysts are consolidating and calcifying and becoming completely 
inactive without any treatment and  
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2. Cysts that have arrived at this stage, not compromising organ functions or causing 
discomfort seem to remain like this or stabilize even further( Junghanss et al,2008). 
CE4 and CE5 cysts do not require any treatment if uncomplicated, CL cysts should not be 
treated, until their parasitic nature has been proven. Long-term follow-up of  with US 
imaging has increased clinicians’ confidence that in selected cases, i.e. when inactive cysts 
are not complicated, treatment can be put on hold. This decision must, however, be 
accompanied and verified by long-term ultrasonographic follow- up. Ten years seem to be 
an adequate time frame ( (Junghanss et al. 2008).  
8.1.7 Comparisons of therapy for E. granulosus  
There have been few studies that have directly compared the various forms of therapy for 
cystic echinococcosis. 
A number of surgical and non-surgical options exist to treat cystic echinococcosis of the 
liver. Pre- and post-intervention chemotherapy with albendazole or mebendazole reduces 
the risk of disease recurrence and intraperitoneal seeding of infection that may develop by 
cyst rupture and spillage occurring spontaneously or during surgery or needle drainage. 
PAIR appears to be more effective treatment method with lower rates of major and minor 
complications, mortality, and disease recurrence. Hospitalization period is also shorter 
compared to patients treated surgically. PAIR is a safe and effective procedure of choice for 
patients with hepatic echinococcosis, and perhaps other anatomic sites of infection such as 
lung, peritoneum, kidney, and other viscera when the medication are ineffective.  Surgery 
should be reserved for patients with hydatid cysts refractory to PAIR because of secondary 
bacterial infection or for those with difficult-to-manage cyst-biliary communication or 
obstruction(Smego,2005) 
8.1.8 Monitoring the response to therapy  
Follow-up visits, including US examination should be done every 3–6 months initially and 
every year once the situation is stable. Leukocyte counts and aminotransferase 
measurements are necessary at monthly intervals to detect adverse reactions. Serum levels 
of the drugs can be measured but only few laboratories have the capacity to determine 
plasma drug levels (Brunetti et al,2010). 
8.1.8.1 Ultrasound  
Radiologic changes are not entirely reliable in assessing response to therapy. However, 
changes seen on ultrasound that seem to correlate with effective therapy include (Khuroo et 
al,1993; Sciarrino et al, 1991): 
1. Reduction in cyst size and volume  
2. Separation of the endocyst from the pericyst and detachment or collapse of membranes 
leading to a split wall (water lily sign)  
3. Decrease in size or number of daughter cysts and/or rupture of vesicles in 
multivesicular cysts  
4. Decrease in fluid within the cyst and increase of the solid component, leading first to 
development of internal echoes within the cyst (heterogeneous echo pattern) and then 
to obliteration of the cyst cavity by echogenic material (pseudotumor echo pattern)  
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5. Thickening and irregularity of the cyst wall  
6. Complete disappearance of the cyst (Figure 7, 8). 
Development of new cysts, increase in its volume or its liquid component and 
disappearance of visibly detaching membrane can be interpreted as relaps.( Echinonet,2005) 
 
Fig. 7. Post percutaneous treatment. B-mod US shows inactive cyst containing membranes 
and coarse echoes. Cyst wall is markedly thickened. 
 
Fig. 8. Post percutaneous treatment.  B-mode US shows collapsed flattened elliptical cyst 
(low pressure within the cyst), germinal layer detached from the cyst wall. 
8.1.8.2 Serology 
Serologic titers usually fall 1-2 years after successful surgery but it is not a rule. Antibodies 
may remain elevated even many years after cyst removal (Rigano et al,2002; Galitza et 
al,2006). Specific IgE antibody titers, IgG4 antibody and arc 5-based tests have been shown 
to be more sensitive than other tests (Baldelli et al,1992; Guisantes et al,1994; Shambesh et 
al,1997; Rigano et al,2002; Galitza et al,2006). There are also some new antigens which can be 
important in post-treatment monitoring. Nouir et al. synthesized recombinant Echinococcus 
granulosus protoscolex recP29 antigen to be preliminarily assessed by ELISA and 
immunoblotting and carried out on 54 young patients with cystic echinococcosis (CE). 
RecP29 ELISA showed a gradual decrease of antibody concentrations in all cured-CE cases 
that were initially (before treatment) seropositive to this antigen or that seroconverted 
following treatment. A complete seronegativity was reached within 3 years post-surgery in 
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all of these cases. They showed that recombinant P29 protein appears prognostically useful 
for monitoring those post-surgical CE cases with an initial seropositivity to this marker ( Ben 
Nouir ,2009). In a recent study of the same author, Echinococcus granulosus protoscolex 
soluble somatic antigens (PSSAs) were assessed for their prognostic value in the serological 
follow-up of young patients treated for cystic echinococcosis (CE), compared to 
conventional hydatid fluid (HF) antigen. They stated that PSSA represents a useful 
candidate to carry out a serologic follow-up of CE ( Ben Nouir  et al,2008). 
One of the major problems of CE is the assesment of serological markers to diagnose 
relapses. Galitza et al. followed six cystic echinococcosis patients who underwent surgery 
for the removal of echinococcal cysts. All were treated with albendazole prior to and 
following treatment. After surgery, no cysts were detected in five of the six patients 
examined. Both ELISA and immunoblot analysis have been used to determine specific IgG, 
IgG4 and IgE activities. Total elimination of IgG and IgG4 was not achieved in any of the 
patients studied. Prior to the first surgery/treatment, specific IgG, IgG4 and IgE antibodies 
were demonstrated in all patients, except one who did not show any IgE activity. The first 
treatment was followed by highly elevated IgE in two patients; in one of them it was further 
combined with an apparent decrease in IgG activity. Repeated treatment with albendazole 
given 0.8-8.5 years after the first treatment/surgery was followed by either moderate or 
highly reduced IgE activity in two patients, respectively, and a slight increase in IgG4 in 
another patient. A third course of treatment, given 2-2.5 years after the second treatment, 
barely affected the antibody activities. The study suggests that anti-echinoccocal antibody 
activity may remain high many years after successful cyst removal. The presence of anti-
echinococcal antibodies after surgery with no cyst detection does not necessarily indicate an 
active echinococcal infection (Galitza et al., 2006).   
8.2 Treatment for Echinococcus multilocularis  
The following principles should be followed for treatment for alveolar echinococcus:  
1. BMZ are mandatory in all patients, temporarily after complete resection of the lesions, 
and for life in all other cases, 
2. Interventional procedures should be preferred to palliative surgery whenever possible, 
3. Radical surgery is the first choice in all cases suitable for total resection of the lesion(s) 
(Brunetti et al,2010). 
8.2.1 Antiparasitic drug treatment 
Long-term BMZ treatment for several years is mandatory in all inoperable AE patients and 
following surgical resection of the parasite lesions. Since residual parasite tissue may remain 
undetected at radical surgery, including liver transplantation(LT), BMZ should be given for 
at least 2 years and these patients monitored for a minimum of 10 years for possible 
recurrence. Pre-surgical BMZ administration is not recommended except in the case of LT. 
The contrandications for medical treatment consist of only the life-threatening side effects of 
the drugs. In cases of pregnancy, the drug should be used with cautions (Brunetti et al,2010). 
The dose of albendazole is 10-15mg/kg/day given in 2 divided doses with a fat-rich meal. 
Continuous treatment with albendazole is preferred instead of intermittent treatment and it 
is well tolerated for more than 20 years. If ABZ is not available or not well tolerated, 
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mabendazole may be given at daily doses of 40–50 mg/kg/day divided into three doses 
with fat-rich meals. Based on experimental data, PZQ has no place in the treatment of 
human AE (Marchiondo et al., 1994). Nitazoxanide has no efficacy for treatment of AE. 
(Kern et al., 2008). Conventional and liposomal amphothericin B have been used as a salvage 
treatment in a few patients who did not tolerate BMZ (Reuter et al., 2003). 
During treatment, the clinican must control liver function tests initially every 2 weeks (first 3 
months), then monthly (first year), then every 3 months.  BMZ administration is crucial in 
all cases of AE, but if an increase above 5 times the upper limit of normal (ULN) of 
aminotransferases is observed, the following steps are recommended: 
1. Check for other causes of the increase (other medication, viral hepatitis, AE-related 
biliary obstruction or liver abscess), 
2. Monitor drug levels,  
3. If ABZ sulfoxide plasma levels are higher than the recommended range of 
concentrations (1–3 mol/L, 4 h after morning drug intake), decrease ABZ dosage and 
shift to the alternative BMZ (MBZ if ABZ and vice versa) and  
4. If an increase over 5×ULN persists, consult a reference centre.  
Decrease of leukocyte count under 1.0×109/L indicates BMZ toxicity and warrants treatment 
withdrawal ( Brunetti et al,2010). 
Medical therapy can improve the quality and length of survival, even though 
benzimidazoles are only parasitostatic and not curative. Approximately one-half the 
patients respond with regression or at least stabilization of their lesion. Survival rates of 53 
to 80 percent at 15 years have been observed with chemotherapy alone compared to 100 
percent mortality at 15 years without treatment(Ammann et al,1990; Wilson et al,1992;  
Wilson et al,1995). 
8.2.2 Surgery  
Radical resection is the primary goal. Whenever possible complete resection of AE lesions 
should be performed.  In principle, radical surgery should be avoided when R0- resection is 
not achievable. Excision of the entire parasitic lesion should follow the rules of tumour 
surgery, with a 2cm safety margin classified according to the quality of resection: (R0: no 
residue; R1: microscopic residue; R2: macroscopic residue). Lesions not confined to the liver 
are not a contraindication to surgery per se, but curative procedures have to meet the 
criteria for R0- resections as well. Lesions in other organs (e.g. brain) should be managed 
either by surgery or by alternative measures. Irrespective of the type of procedure, 
concomitant BMZ treatment is mandatory for at least 2 years. LT is contraindicated in the 
presence of extra-hepatic locations and if immunosuppressive drugs and/or BMZ are 
contraindicated. 
Li et al published their experiences in treatment of human multiorgan alveolar echinococcis 
by surgery and drugs. Among 17 cases, 8 cases achieved an excellent effect after taking 
liposomal albendazole, 3 cases received radical hepatectomy and 1 case pneumonectomy 
with a better effect, 1 case of palliative liver transplantation had lung metastasis and stayed 
on a long-term therapy of liposomal albendazole. Another case of liver transplantation 
received a long-term postoperative chemotherapy. And the metastases of lung and brain 
www.intechopen.com
 Zoonosis 354 
were found. Three operative cases suffered serious complications in liver and brain and 
received a long-term chemotherapy. One of them died of serious brain complications after a 
6-month follow-up. And one advanced AE patient died at home due to a refusal of any 
further treatment. They concluded that  multi-organ AE patients may have a prolonged 
survival and an improved clinical outcome (Li et al,2010) 
8.2.3 Liver transplantation 
The indications for liver transplantation are: 
1. Severe liver insufficiency (secondary biliary cirrhosis or Budd-Chiari syndrome) or 
recurrent life-threatening cholangitis, 
2. Inability to perform radical liver resection 
3. Absence of extra-hepatic AE locations: cases with residual AE in lung or abdominal 
cavity should be regarded as exceptional indications,  (Scheuring et al., 2003). 
Liver transplantation can be performed in cases with nonresectable lesions and severe liver 
compromise, but residual parasite tissue may be prone to more rapid growth because of the 
immunosuppression that is required following transplantation. In order to minimize the 
risk, post-transplant adjuvant chemotherapy with a benzimidazole is advised (Bresson-
Hadni,1999). Moray et al. reported 2 patients with advanced alveolar echinococcal disease 
that invaded both lobes of the liver and neighboring vital structures including the inferior 
vena cava. Despite the technical difficulty of the surgery, both patients were successfully 
treated with living donor liver transplantation. The author concludes that liver 
transplantation should be accepted as a life-saving treatment of choice in patients with 
alveolar echinococcosis for whom there is no other medical or surgical treatment options 
(Moray et al,2009).  
Liver transplantation  is currently contraindicated in patients with residual or metastatic 
alveolar echinococcosis lesions. Hadni et al. evaluated the long-term course of such patients 
who underwent LT and were subsequently treated with benzimidazoles. They found that 
high doses of immunosuppressive drugs, the late introduction of therapy with 
benzimidazoles, its withdrawal due to side effects, and nonadherence to this therapy 
adversely affected the prognosis. They stated that potential recurrence of disease, especially 
in patients with residual or metastatic AE lesions, should not be regarded as a 
contraindication to LT when AE is considered to be lethal in the short term (Bresson-Hadni 
et al,2011). 
8.2.4 Endoscopic and Percutaneous Interventions (EPI) 
EPIs are indicated for complications if surgery is felt to be too high a risk and total resection 
of the lesions cannot be safely performed. Main indications include liver abscess due to 
bacterial infection of necrotic lesions, jaundice due to bile duct obstruction with or without 
acute cholangitis, hepatic or portal vein thrombosis and bleeding of oesophageal varices 
secondary to portal hypertension. But EPI spread parasite material and should be avoided if 
postinterventional BMZ is not possible. EPIs together with BMZ avoid palliative surgery 
and can improve life expectancy and quality of life of AE patients. In addition, radical 
resection which was not possible initially may become feasible following the shrinkage of a 
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necrotic cavity after percutaneous drainage. Risks of EPIs include haemorrhage (for all 
procedures) and internal bile leakage or prolonged bile leakage through an external drain 
for bile duct drainage. 
8.2.5 Monitoring treatment 
After initiation of any type of treatment, long-term follow-up by US at shorter intervals and 
CT and/or MRI at intervals of 2–3 years, should be planned. Progression is documented by 
enlargement of lesions over time. Determination of ABZ sulfoxide blood levels, 4 h after the 
morning dose, is recommended 1, 4 and 12 weeks after starting treatment, and 2–4 weeks 
after each dose adjustment with an estimated therapeutic range of 0.65–3 mol/L. ABZ 
dosage should be reduced if 2 sequential measurements are above 10 mol/L. Monitoring of 
MBZ plasma level is possible; plasma levels should be over 250 nmol/L (WHO-IWGE, 
1996). 
Scheuring et al. reported a case of advanced alveolar echinococcosis which was diagnosed 
histologically from a subcutaneous nodule with skin inflammation on the right leg. The 
patient showed bone metastases in the lower thoracic spine and the left third toe by 
hematogenic spread. The patient was treated with albendazole and remained stable for 6 
years. When progression of AE occurred the therapy was changed to mebendazole, 
resulting in a stable condition for further 4 years. The author showed that serum levels of 
Anti-Em2 and anti-Em18 antibodies decreases rapidly after complete surgical removal of the 
lesions. (Scheuring et al., 2003). Interpretation of serological results in patients treated with 
BMZ without radical resection is more complex (Tappe et al., 2009).  
Ammann et al showed that in patients with curative surgery, the profiles of specific 
antibodies against EmII/3-10 antigen normalized within 3 years but remained above the 
cut-off value in 40% of non-resectable group. This lack of normalization was associated with 
lower bioavailability of mebendazole. AE-recurrence after 'radical' surgery  was associated 
with high anti-EmII/3-10 concentrations.Presence of anti-II/3-10/Em18-antibodies is more 
likely to reflect the presence of a viable metacestode with disappearance of such antibodies 
indicating lesions dying-out (Ammann et al., 2004). 
BMZ are only parasitostatic and many studies have demonstrated that they do not kill E. 
multilocularis metacestodes (WHO-IWGE, 1996). Methods to assess early therapeutic efficacy 
are lacking. Recently, AE liver lesions were reported to exhibit increased F-18-
fluorodeoxyglucose (FDG) uptake in positron emission tomography. This may be an 
important tool when there is a tendency to stop treatment. Although it does not provide 
direct evidence of E. multilocularis viability and recurrence may occur, this technique, 
together with the follow-up of specific serum antibodies, may support decision making and 
follow-up after BMZ withdrawal in highly selected patients. (Reuter et al., 2004; Stumpe et 
al., 2007). 
9. Economic burden of Echinococcosis 
Echinococcus is an important public health and economic problem in endemic regions of the 
world. In humans, CE may have various consequences, including direct costs such as 
diagnosis, hospitalisation, surgical or percutaneous treatments, medical therapy, post-
treatment care, travel for both patient and family members as well as indirect costs such as  
www.intechopen.com
 Zoonosis 356 
mortality, suffering and social consequences of disability, loss of working days or 
“production”, abandonment of farming or agricultural activities by affected or at-risk 
persons (Battelli, 2009). In the literature, there are some studies evaluating the overall 
economic losses due to human and animal disease. The total estimated cost of human CE in 
Peru is U.S.$2,420,348  per year. Total estimated livestock-associated costs due to CE ranges 
from U.S.$196,681  if only direct losses (i.e., cattle and sheep liver destruction) are taken into 
consideration to U.S.$3,846,754 if additional production losses (liver condemnation, 
decreased carcass weight, wool losses, decreased milk production) are accounted for. An 
estimated 1,139 (95% CI: 861–1,489) disability adjusted life years (DALYs) are also lost due 
to surgical cases of CE (Moro et al,2011). 
A study from Spain showed that the overall economic loss attributable to CE in humans and 
animals in 2005 was estimated at 148 964 534 euros. Human-associated losses were 
estimated at €133 416 601 and animal-associated losses at €15 532 242(Benner et al,2010). 
Another study from Turkey where the mean prevalence rates of the cystic echinococcosis 
disease were calculated to be 7.4% in cattle, 46.3% in sheep and 10.9% in goats, the 
production losses in an infected ruminant were estimated as US$ 139.2  for cattle, US$ 13.7  
for sheep, and US$ 13.9  for goats. The nation-wide annual losses due to CE were estimated 
as US$ 32.4 million (26.2–39.1) for cattle, US$ 54.1 million (43.8–65.5) for sheep and US$ 2.7 
million (2.2–3.3) for goats. The nation-wide production losses due to CE in Turkey in 2008 
were calculated as US$ 89.2 million (72.2–107.9) (Sarıozkana&Yalcın, 2009). 
In a report from China quantifying the economic losses due to Echinococcus multilocularis 
and E. granulosus in Shiqu County, Sichuan; showed that human losses associated with 
treatment costs and loss of income due to morbidity and mortality, in addition to 
production losses in livestock due to E. granulosus infection was estimated to reach 218,676 
U.S. dollars if only liver-related losses in sheep, goats, and yaks are taken into account. This 
was equal to approximately 3.47 U.S. dollars per person annually or 1.4% of per capita gross 
domestic product. They stated that  total annual losses could be nearly 1,000,000 U.S. dollars 
if additional livestock production losses were assumed (Budke et al,2005). 
A report from Tunisia states that Echinococcosis causes significant direct and indirect losses 
in both humans and animals of approximately US dollars 10-19 million annually 
(Majorowski et al,2005). 
The awareness of the social and economic burden of the disease accelerated the use of 
control and prevention programmes. 
10. Control of the disease 
10.1 Control of E. granulosus infection 
Prevention of cystic echinococcosis often can be achieved mostly by avoiding close contact 
with dogs. Careful washing of vegetables and contaminated fresh produce can also reduce 
infection. Prohibition of home-slaughter of sheep will prevent dogs from consuming 
infected viscera, thus disrupting the life cycle of the parasite(23). 
In some countries where an eradication program has been attempted (eg, Iceland, Australia 
and New Zealand), a marked decrease in human cases has occurred (Craig et al,2006). 
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Vaccination of livestock and dogs, special educational programmes, development of better 
diagnostics for definitive hosts and human beings (including dog coproantigen detection), 
more effective antiparasitic treatments and the use of mathematical models to simulate best 
possible cost-eff ective interventions, will improve the hydatid control programmes(Craig et 
al,2007).  
Albendazole (ABZ), along with levamisol and ivermectin, is one of the most used 
antiparasitic drug in sheep, goats, cattle, horses and pigs. It has been shown that ABZ is not 
detected in the plasma of treated sheep at any time after administration, but its active 
metabolites, albendazole sulphoxide and albendazole sulphone are detectable for about 48 
hr after administration. Oxfendazole (OXF), another benzimidazole like ABZ, has broad-
spectrum activity against larval stages of gastrointestinal roundworms, tapeworms, and 
lungworms in many animal species(Lanusse et al, 1995).  
In a study of Gavidia et al, effects of Oxfendazole alone (an antiparasitic drug used in 
animals), Oxfendazole plus Praziquantel, and Albendazole plus Praziquantel against 
hydatid cysts in sheep were evaluated. They demonstrated that over 4 to 6 weeks of 
treatment, Oxfendazole at 60 mg, combination Oxfendazole/Praziquantel and combination 
Albendazole/Praziquantel were successful schemas that could be added to control 
measures in animals. OXF has not yet been approved for human(Gavida et al,2010). 
10.2 Control of E. multilocularis infection 
Currently, there is no reliable and cost-effective method for sustainable control or 
eradication of E. multilocularis in the sylvatic cycle. Large field trials have been conducted 
since 1995 in Germany for mass treatment of red foxes with baits containing 50 mg of 
praziquantel. The baits are repeatedly distributed by light aircraft. Although first reports 
stated that reducing the prevalence of E. multilocularis in the fox population was possible, 
other trials suggest that long-term control of E. multilocularis, in the sylvatic cycle in large 
areas, is extremely difficult and costly(Eckert & De-Plazes ,2004). In another study in Zurich,  
praziquantel-containing baits were distributed every month for 2 years in six areas of 1 km2 
inhabited by foxes. Preliminary results indicate a significant decrease of the environmental 
contamination with E. multilocularis eggs and of parasite prevalences in voles in baited areas 
compared to those in control areas (Heglin et al,2003). Monthly praziquantel given to dogs 
in a 10-year field trial in Alaska was effective in reducing egg contamination(Rausch et 
al,1990). 
In areas of endemic infection with low prevalences of E. multilocularis infection in dog and 
cat populations, mass treatment of these animals may currently be neither indicated nor 
feasible. In these circumstances it may be appropriate to give regular praziquantel treatment 
every 4 weeks only to dogs and cats having access to infected rodents(Eckert & De-Plazes 
,2004).  
For persons at especial risk (for example, laboratory personnel working with E. multilocularis 
eggs or handling infected definitive hosts, children after exposure to feces of infected foxes, 
etc.), repeated serological screening for anti-E. multilocularis antibodies by using highly 
sensitive and specific tests is recommended, with the aim of detecting an infection in an 
early stage or excluding it with a reasonable degree of probability. Special safety precautions 
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are recommended for laboratory and field workers possibly exposed to infective E. 
multilocularis eggs (Eckert et al,2001). 
11. Vaccination  
The life-cycles of E. granulosus and E. multilocularis include two hosts: an intermediate and a 
definitive host. Prevention of transmission to either host can reduce or even eliminate the 
infection in human and livestock populations. Vaccination is the most important issue for 
the control of the disease.  Vaccination of humans would provide the most direct means to 
prevent echinococcosis but the economic burden might be very high. Instead, vaccination of 
the normal animal hosts of the parasites, indirectly achieves a reduction in human incidence 
by decreasing or removing the source of infective material for humans. The latter strategy 
would be considerably less expensive to develop and implement.(Craig et al, 2007) 
The sylvatic nature of the lifecycle of E. multilocularis makes a vaccination approach 
impossible.(Zhang &McManus 2006) But a defined recombinant vaccine for ovine cystic 
echinococcosis (called EG95) was developed in 1996 by the groups of Marshall Lightowlers 
and David Heath in Australia and New Zealand. The native molecule is 24.5 kDa and 
cloned as a 16.5 cDNA fusion peptide of 155 aminoacids with a fibronectin-like motif under 
the control of seven closely related genes. EG95 vaccine, contains a purified recombinant 
protein of the parasite oncosphere as well as an adjuvant. Echinococcus vaccines would 
ideally prevent oncosphere development to hydatid cysts in sheep, and thus stop the 
development of adult gravid tapeworms in dogs. Two doses of the vaccine are administered 
initially one month apart, followed by a required annual booster. This vaccine has been 
studied in animals and appears to afford 95 percent protection to sheep, cattle and goats in 
preliminary trials(Heath et al,2003; Lightowers et al,1996,2000; Zhang,2003). 
The EG95 hydatid vaccine was licensed for application in China in June 2007 and is 
currently being assessed for registration in Argentina. Field trials are underway in 
Argentina in the Tehuelche communities of Chubut province and the Mapuche communities 
of Rio Negro province. Clinical trials are underway in Turkey with a clostridial ⁄ EG95 
combination vaccine for sheep. It would be better to incorporate EG95 with an existing 
commercial livestock vaccine such as tetanus, leptospirosis, or sheep orf.( Bethony  et 
al,2011) 
Compared with the major advances in vaccinating sheep against E. granulosus, there is 
currently no practical vaccine available for use in canid hosts of E. granulosus. However, a 
vaccine that reduces egg production would potentially be sufficient to limit transmission in 
areas where the parasite is endemic. In fact, dogs are the major definitive host for E. 
granulosus and plays a very important role in transmission. Interruption of the parasite life 
cycle in the dog host can provides a very acceptable and cost-effective complementary 
method for control by vaccination.(Zhang & McManus ,2006) Nevertheless, a series of 
experiments to induce immunity in dogs through vaccination have been carried out, with 
some encouraging results.  
Zhang et al. used differential-display PCR to isolate three differentially expressed sequences 
(egM4, egM9 and egM123) belonging to a novel egM family of proteins expressed 
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exclusively by mature adult worms (MAWs) of E. granulosus and associated with adult 
worm maturation and/or egg development(Zhang et al,2003b). Subsequently, the three 
genes were subcloned into an expression vector that expressed the molecules as soluble 
glutathione S-transferase (GST) fusion proteins in Escherichia coli. The three fusion proteins 
were purified for vaccine trials in which the dogs were vaccinated and necropsied 45 days 
after challenge infection (Zhang et al,2006). Compared with worms in the control dogs that 
received GST, the three recombinant proteins induced a high level of protection (97–100%) 
in terms of suppression of worm growth and, especially, of egg development and 
embryogenesis. This study was the first to demonstrate protection against E. granulosus in 
dogs vaccinated with recombinant proteins derived from MAWs. 
Another group isolated a single copy gene (EgA31) from E. granulosus encoding a 
paramyosin-like 66-kDa fibrillar protein present in the muscles and tegument of adult 
worms(Fu et al, 1999). A recombinant form of EgA31 induced significant cellular immune 
responses in lymph nodes from dogs after intradermal injection( Fu et al,2000; Saboulard et 
al, 2003). Subsequently, a polypeptide encoded by the Pst I–Hind III fragment of the 
complete EgA31 cDNA was shown to be the most potent antigenically during infection in 
the dog (Saboulard et al,2003). Surprisingly, neither recombinant forms of EgA31 nor the Pst 
I–Hind III fragment were tested for protective efficacy in dogs challenged with E. granulosus. 
12. Conclusion 
Echinococcosis is a zoonotic parasitic disease distributed widely around the world and is an 
important cause of human morbidity and mortality, particularly in developing countries. 
Although imaging and immunological techniques for diagnosing CE and AE are improved, 
elimination of the disease is still difficult with current treatment modalities. Surveillance 
programmes and monitoring systems are very important tools in disease control as well as 
vaccination, although there is still no reliable and cost effective method for sustainable 
control or eradication of AE. Vaccination is the most reliable method in control of CE. The 
EG95 vaccine of livestock animals has considerable impact on management of hydatid 
disease in endemic areas and achieves a reduction in human incidence.  Nevertheless, 
development of EG95 as a human vaccine would provide the most direct way of preventing 
the disease and be important in reduction of human morbidity and mortality caused by 
hydatid disease in endemic areas. 
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